Effects of a locally administered risedronate/autogenous bone graft combination on bone healing in a critical-size rabbit defect model

[1] Giannoudis P(2007)Can we accelerate fracture healing? A critical analysis of the literature Injury 38 S81-S89

[2] Psarakis S(2019)Autogenous bone graft versus bovine bone graft in association with platelet-rich plasma for the reconstruction of alveolar clefts: a pilot study Cleft Palate Craniofac J 56 134-140

[3] Kontakis G(1989)Antiresorptive dose-response relationships across three generations of bisphosphonates Drugs Exp Clin Res 15 389-396

[4] Bezerra BT(2020)History of risedronate Bone 137 115407-240

[5] Pinho JNA(2018)Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 391 230-759

[6] Figueiredo FED(2008)Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733-2195

[7] Brandão JRMCB(2008)Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase J Med Chem 51 2187-1184

[8] Ayres LCG(2019)Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial Arthritis Rheumatol 71 1174-2410

[9] Da Silva LCF(2007)Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2397-e16

[10] Sietsema WK(2010)Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort BMJ 341 c4444-675

[1] Giannoudis P(2007)Can we accelerate fracture healing? A critical analysis of the literature Injury 38 S81-S89

[2] Psarakis S(2019)Autogenous bone graft versus bovine bone graft in association with platelet-rich plasma for the reconstruction of alveolar clefts: a pilot study Cleft Palate Craniofac J 56 134-140

[3] Kontakis G(1989)Antiresorptive dose-response relationships across three generations of bisphosphonates Drugs Exp Clin Res 15 389-396

[4] Bezerra BT(2020)History of risedronate Bone 137 115407-240

[5] Pinho JNA(2018)Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 391 230-759

[6] Figueiredo FED(2008)Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733-2195

[7] Brandão JRMCB(2008)Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase J Med Chem 51 2187-1184

[8] Ayres LCG(2019)Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial Arthritis Rheumatol 71 1174-2410

[9] Da Silva LCF(2007)Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2397-e16

[10] Sietsema WK(2010)Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort BMJ 341 c4444-675